Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

EXACT Sciences Corporation

Healthcare US EXAS

NoneUSD
0.00(0%)

Last update at 2026-04-23T21:04:23.732070Z

Day Range

--
LowHigh

52 Week Range

38.81104.00
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap20026.08M
  • VolumeNone
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA71.46M
  • Revenue TTM3246.99M
  • Revenue Per Share TTM17.21
  • Gross Profit TTM 2262.84M
  • Diluted EPS TTM-1.1

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -203.88800M -1036.16100M -201.74600M -632.57000M -842.50600M
Minority interest - - - - -
Net income -207.94900M -1028.85700M -204.14900M -623.50600M -595.62500M
Selling general administrative 888.67M 1420.60M 1394.60M 737.30M 801.26M
Selling and marketing expenses 1050.18M 247.50M 225.70M 846.01M 861.89M
Gross profit 2262.84M 1918.67M 1762.17M 1509.88M 1308.33M
Reconciled depreciation 221.58M 214.86M 206.61M 197.56M 180.35M
Ebit -99.07900M -1004.18700M -177.32500M -577.54200M -835.46800M
Ebitda 122.50M -789.32800M 29.28M -480.09200M -740.46700M
Depreciation and amortization 221.58M 214.86M 206.61M 97.45M 95.00M
Non operating income net other - - - -19.42500M 31.78M
Operating income -99.07900M -1048.70300M -215.01200M -577.54200M -835.46800M
Other operating expenses 3346.07M 3807.57M 2714.78M 2661.82M 2602.55M
Interest expense 32.87M 31.97M 24.42M 19.63M 18.61M
Tax provision 4.06M -7.30400M 2.40M -9.06400M -246.88100M
Interest income - - - - -
Net interest income -39.36100M -37.27000M -29.77100M -19.63400M -18.60600M
Extraordinary items - - - - -
Non recurring - - - 15.97M 20.21M
Other items - - - - -
Income tax expense 4.06M -7.30400M 2.40M -9.06400M -246.88100M
Total revenue 3246.99M 2758.87M 2499.77M 2084.28M 1767.09M
Total operating expenses 2361.92M 2967.37M 1977.18M 2087.43M 2143.80M
Cost of revenue 984.15M 840.20M 737.60M 574.39M 458.76M
Total other income expense net -104.80900M 12.54M 13.27M -55.02800M -7.03800M
Discontinued operations - - - - -
Net income from continuing ops -207.94900M -1028.85700M -204.14900M -623.50600M -595.62500M
Net income applicable to common shares - - - -623.50600M -595.62500M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5860.63M 5928.14M 6471.33M 6226.87M 6684.88M
Intangible assets 919.92M 1009.69M 1890.40M 1956.24M 2094.41M
Earning assets - - - - -
Other current assets 126.28M 122.05M 85.63M 73.90M 74.12M
Total liab 3459.58M 3525.89M 3326.03M 3183.71M 3297.25M
Total stockholder equity 2401.05M 2402.25M 3145.30M 3043.16M 3387.64M
Deferred long term liab - - - - -
Other current liab 425.99M 366.06M 14.82M 309.46M 30.97M
Common stock 1.91M 1.86M 1.81M 1.78M 1.74M
Capital stock 1.91M 1.86M 1.81M 1.78M 1.74M
Retained earnings -4705.98100M -4498.03200M -3469.17500M -3265.02600M -2641.52000M
Other liab - - - 345.06M 417.78M
Good will 2368.05M 2366.68M 2367.12M 2346.04M 2335.17M
Other assets - - - 36.68M 74.59M
Cash 956.00M 600.89M 605.38M 242.49M 315.47M
Cash and equivalents - - - - -
Total current liabilities 641.15M 732.19M 514.70M 412.75M 517.07M
Current deferred revenue - - 341.68M - 398.56M
Net debt 1566.70M 2153.87M 1949.35M 2204.38M 2046.93M
Short term debt 39.29M 276.56M 79.38M 28.37M 19.71M
Short long term debt - 249.15M 50.00M - -
Short long term debt total 2522.70M 2754.76M 2554.72M 2446.87M 2362.40M
Other stockholder equity 7102.77M 6899.37M 6611.24M 6311.64M 6028.86M
Property plant equipment - - - 684.76M 754.47M
Total current assets 1555.85M 1571.42M 1194.37M 982.26M 1426.24M
Long term investments - - - - -
Net tangible assets - - - 697.12M -1041.94700M
Short term investments 8.71M 437.14M 172.27M 389.56M 715.00M
Net receivables 298.65M 248.97M 203.62M 158.04M 216.65M
Long term debt 2327.18M 2321.07M 2314.28M 2186.11M 2180.23M
Inventory 166.20M 162.38M 127.47M 118.26M 104.99M
Accounts payable 175.87M 89.57M 78.82M 74.92M 67.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.36M -0.94400M 1.43M -5.23600M -1.44300M
Additional paid in capital - - - - -
Common stock total equity - - - 1.78M 1.74M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -3265.02600M -2641.52000M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 185.81M 169.72M -287.54600M 90.58M 74.59M
Deferred long term asset charges - - - - -
Non current assets total 4304.78M 4356.72M 5276.97M 5244.62M 5258.65M
Capital lease obligations 195.52M 184.54M 190.45M 210.76M 201.88M
Long term debt total - - - 2186.11M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 376.51M -442.15500M 49.68M 278.76M -387.77200M
Change to liabilities - - - -52.18000M 169.80M
Total cashflows from investing activities 195.12M -442.15500M - 74.07M -1082.08500M
Net borrowings -249.17200M 216.75M - 50.00M -23.74900M
Total cash from financing activities -338.09000M 231.87M 159.77M 76.48M 8.47M
Change to operating activities - - - -22.05400M -74.62000M
Net income -207.94900M -1028.85700M -204.14900M -623.50600M -595.62500M
Change in cash 349.36M -3.03900M 366.88M -72.97800M -1175.82600M
Begin period cash flow 606.64M 609.67M 242.79M 315.77M 1491.59M
End period cash flow 956.00M 606.64M 609.67M 242.79M 315.77M
Total cash from operating activities 491.44M 210.54M 156.12M -223.55900M -102.23600M
Issuance of capital stock - - - 0.00000M 0.00000M
Depreciation 221.58M 214.86M 206.61M 197.56M 180.35M
Other cashflows from investing activities 28.27M -0.22500M - 9.77M -0.74400M
Dividends paid - - 169.52M - 37.51M
Change to inventory -3.77200M -34.91100M -7.69000M -13.23100M -9.22100M
Change to account receivables -48.89100M -46.25900M -43.41600M 61.09M 25.15M
Sale purchase of stock 26.54M 31.23M 28.34M 25.49M 23.07M
Other cashflows from financing activities -117.36400M -17.75400M 21.79M 44.47M 9.15M
Change to netincome - - - 181.28M 195.25M
Capital expenditures 134.66M 135.99M 124.19M 214.46M 135.77M
Change receivables - - - 61.09M 25.15M
Cash flows other operating - - - 118.41M -129.54900M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -73.00800M -1175.84900M
Change in working capital 121.83M -56.01200M -0.34200M -26.37700M 111.11M
Stock based compensation 217.67M 214.88M 231.31M 206.82M 253.06M
Other non cash items 139.86M 875.78M -76.35500M 33.84M 202.04M
Free cash flow 356.78M 74.55M 31.93M -438.02100M -238.00200M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EXAS
EXACT Sciences Corporation		 - -% - - 243.90 6.17 8.34 6.65 411.57
TMO
Thermo Fisher Scientific Inc		 8.08 1.70% 482.03 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 8.56 4.81% 186.64 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 0.97 0.71% 138.37 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 4.01 0.72% 564.74 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXACT Sciences Corporation

5505 Endeavor Lane, Madison, WI, United States, 53719

Key Executives

Name Title Year Born
Mr. Kevin T. Conroy Chairman of The Board & CEO 1966
Mr. Jeffrey T. Elliott CFA Exec. VP, CFO & COO 1978
Mr. D. Scott Coward Chief Legal Officer 1965
Mr. Graham P. Lidgard Emeritus Chief Science Officer 1949
Mr. Everett V. Cunningham Chief Commercial Officer 1966
Dr. Jorge A. Garces Ph.D. Chief Science Officer 1972
Mr. Sri Kalluri Chief Information Officer NA
Ms. Megan Jones Associate Mang. of Investor Relations NA
Mr. Tim Caprez Chief Compliance Counsel & VP NA
Mr. Vic Parker Head of Sales NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions